Table 3.
CRs by Dose Level
| Dose Level (units/m2)/Cohort | No. of CRs | Aplasia | Response to CPX-351 | Age (years) | CPX-351 as Salvage | Duration of First CR (months) | Duration of CPX-351 Remission (months) |
|---|---|---|---|---|---|---|---|
| 32 | 3 | 2 | CRp | 55 | > 2nd | 2 | 5.4 |
| 43 | 3 | 2 | CR (ALL) | 44 | 1st | 8 | 0.5 |
| CR | 74 | > 2nd | 7 | 6.0 | |||
| 76 | 3 | 1 | CR | 60 | 1st | 3 | 1.6 |
| 101 | 20 | 13 | CR | 36 | 1st | 12 | < 12 |
| CR | 59 | 1st | 12 | 16+ | |||
| CR | 56 | 1st | 20 | 15+ T | |||
| CR | 72 | 1st | 8 | 9 | |||
| CR | 37 | 2nd | 24 | 18+ T | |||
| 134 | 6 | 4 | CR | 62 | 1st | 0 | 6.7 |
| CR | 67 | 1st | 56 | 22+ |
Abbreviations: CR, complete remission; CRp, CR with incomplete platelet recovery; ALL, acute lymphoblastic leukemia; T, consolidated with stem- cell transplantation.